Serial Number | 90618193 |
Word Mark | ANAKURIA THERAPEUTICS |
Filing Date | Thursday, April 1, 2021 |
Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
Status Date | Tuesday, August 29, 2023 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | NOT AVAILABLE |
Name/Portrait Description and/or Consent Statement | The name(s), portrait(s), and/or signature(s) shown in the mark does not identify a particular living individual. |
Goods and Services | Pharmaceutical preparations and substances for the prevention, treatment and diagnosis of cancer, diabetes, and heart disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of neurodegenerative diseases, namely, Alzheimer's disease, Parkinson's disease, and Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of immune disorders, namely, psoriasis, rheumatoid arthritis, lupus, Crohn's disease, inflammatory bowel disease, and multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of metabolic, endocrine, cardiovascular, oncological, gastrointestinal, musculoskeletal, nephrological, mitochondrial, autoimmune, and neurological related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of rare genetic diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of Leigh's syndrome, Friedrich's ataxia, lymphangioleiomyomatosis (LAM) and tuberous sclerosis; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of obesity and obesity related diseases; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of age-related diseases; pharmaceutical preparations and substances for modulating the catabolic or anabolic response to nutrients; pharmaceutical preparations and substances for the prevention, treatment and diagnosis of any disease related to muscle wasting diseases and conditions, including, cachexia, sarcopenia and muscle wasting due to prolonged immobilization; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting caloric intake and absorption; pharmaceuticals, therapeutics and nutraceuticals for use as active ingredients in foods, namely, dietary supplements; pharmaceuticals, therapeutics and nutraceuticals for use as food additives for medical purposes, namely, amino acids; dietetic substances for medical purposes, namely, dietetic foods such as dietary beverage supplements adapted for medical use; nutritional additives for medical purposes, namely, amino acids; pharmaceutical preparations and substances for the modulation of appetite, namely, appetite suppressants and satiety inducers |
Goods and Services | Pharmaceutical research and development; drug development and discovery services; medical and scientific research; providing medical and scientific research information in the field of pharmaceuticals |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Friday, July 9, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Friday, July 9, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Anakuria Therapeutics, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Cambridge, MA 02138 |
Event Date | Event Description |
Tuesday, August 29, 2023 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
Tuesday, August 29, 2023 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
Tuesday, August 29, 2023 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
Monday, May 15, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
Monday, May 15, 2023 | FINAL REFUSAL E-MAILED |
Monday, May 15, 2023 | FINAL REFUSAL WRITTEN |
Tuesday, November 15, 2022 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
Wednesday, May 18, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Wednesday, May 18, 2022 | LETTER OF SUSPENSION E-MAILED |
Wednesday, May 18, 2022 | SUSPENSION LETTER WRITTEN |
Monday, May 16, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, May 16, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, May 16, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Tuesday, November 16, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, November 16, 2021 | NON-FINAL ACTION E-MAILED |
Tuesday, November 16, 2021 | NON-FINAL ACTION WRITTEN |
Tuesday, November 16, 2021 | ASSIGNED TO EXAMINER |
Friday, July 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Monday, April 5, 2021 | NEW APPLICATION ENTERED |